Exclusive: Haofeng Medical Secures Nearly RMB 100 Million Strategic Financing to Strengthen Its Position as a Leading Interventional Medical Device CDMO Platform

VCBeat learned at the earliest opportunity that recently, Shanghai Haofeng Medical Technology Co., Ltd. (“Haofeng”) has completed a new strategic financing round of nearly RMB 100 million, led by funds under Huayin Jintou at China Medical City, Taizhou. This round of financing will be primarily used for Haofeng Medical's production capacity expansion, business development, and global layout, further solidifying its platform advantages in the CDMO sector for interventional medical devices. Previously, the company had received continuous investment from several well-known institutions, including Zhuhai High-Tech Gold Investment, Cenova Capital, and CUI CAPITAL.

As China’s first full-chain interventional medical device CDMO platform company, Haofeng has evolved since its inception in 2013—starting with precision machining of access consumables—through over a decade of development, transforming from a single supplier of precision-machined access consumables and production equipment into a comprehensive CDMO group covering four industrial platforms: “Equipment–Components–Materials–Energy.” Headquartered in Life Bay at the Lingang New Area of Shanghai, the Group has established R&D and manufacturing bases in Taizhou, Jiangsu Province, and Zhuhai, Guangdong Province, with overseas offices concurrently deployed, encompassing a total area exceeding 30,000 m².

The core pain point in the interventional medical device industry lies in the fact that while R&D prototypes can be successfully developed, achieving scalable, consistent, and stable mass production remains a challenge. Haofeng’s solution is to build four major platforms, creating a closed-loop industrial ecosystem.

Focusing on contract research, development, and manufacturing (CRDMO) for three categories of access medical devices—balloons, catheters, and guidewires—the company serves multiple clinical sectors, including neurointervention, coronary intervention, peripheral intervention, structural heart disease, electrophysiology, urological intervention, oncological intervention, and orthopedics. The platform offers adjustable-curve sheaths ranging from 6F to 24F, with bending angles up to 270°, supporting unidirectional, bidirectional, tri-directional, quad-directional, and even three-dimensional deflection. In guidewire processing, the minimum grinding diameter reaches 0.04 mm, with tolerance controlled within ±0.005 mm, enabling multi-step and multi-taper variable-diameter machining.

Specializing in the R&D, modification, and extrusion processing of medical-grade materials, we provide core products such as balloon tubing, single-lumen tubes, multi-lumen tubes, double-layer composite tubes, PET heat-shrink tubing, PTFE-lined tubes, and piezoelectric ceramic capillaries. Notably, for piezoelectric ceramic capillaries with an outer diameter of 0.6 mm or less, the diameter tolerance is controlled within 50 μm, density exceeds 98%, and flexural strength surpasses 100 MPa, making them suitable for use as 360° annular scanning elements in intravascular ultrasound (IVUS) catheters. The performance of specialty medical materials and tubing made from piezoelectric ceramics, PEEK, PI, and other materials matches that of imported products, positioning us as one of the first CDMO enterprises in China to offer domestic alternatives to such imported materials.

Haofeng Medical’s Most Differentiated “Hidden Champion” BusinessAs the leading domestic supplier of production and testing equipment for all categories of interventional consumables, the company covers product lines including balloon catheters, interventional catheters, and interventional guidewires, with its equipment exported overseas. Its independently developed electromagnetic heating automatic balloon stretching and molding integrated machine reduces the production cycle to 1.5 minutes per unit, improving efficiency by more than 10 times; the fully automatic coiling production line achieves a daily output of nearly 10,000 coils, increasing efficiency by 8 times.

Undertakes R&D and contract manufacturing of Class II and Class III active medical devices, including those for radiofrequency, microwave, and cryoablation, providing end-to-end services from circuit design, software development, and structural design to production management.

Haofeng Medical has always adhered to the principle of "not being a terminal brand operator," thereby avoiding conflicts of interest with customers over the terminal market from the source.

This clear role positioning is the key to Haofeng Medical winning customer trust in the CDMO sector. Haofeng Medical proposes three keywords for domestic interventional device CDMO services—Deliverability, Consistency, and Transparency—directly addressing the industry’s pain point of “robust R&D but weak delivery.”

As of now, Haofeng Medical has served over 60 domestic and international partner clients, secured more than 20 commercial production orders, collaborated with over 10 listed companies, and engaged with more than 30 overseas clients. Its product portfolio spans nine major fields: neurointervention, coronary intervention, peripheral intervention, structural heart disease, electrophysiology, urology, oncology intervention, gastrointestinal tract, and orthopedics. The Group employs over 500 staff members, including an engineering team of more than 80 professionals, and holds over 350 national patents and software copyrights. Its subsidiary, M-Duke Medical Technology (Shanghai) Co., Ltd., was re-certified as a National High-Tech Enterprise in 2025. Both Haofeng Medical and M-Duke Medical have been recognized as Shanghai “Specialized, Refined, Differential, and Innovative” (SRDI) Small and Medium-sized Enterprises.

Driven by the accelerating aging of the population, rising penetration rates of interventional procedures, and the expedited process of domestic substitution, China’s interventional medical device market is experiencing a period of rapid growth. Meanwhile, the comprehensive implementation of the Medical Device Registrant Holder (MAH) system has led an increasing number of innovative medical device companies to outsource their R&D and manufacturing to professional CDMO institutions, resulting in continuous expansion of industry demand.

As a leading high-end interventional medical device CDMO platform in China, Haofeng will continue to adhere to its positioning of “not becoming an end-product brand owner,” deepen the development of its four major platforms, continuously increase R&D investment and expand production capacity, and constantly enhance service capabilities and product quality, so as to provide global interventional medical device brands with higher-quality, more efficient, and more comprehensive full-lifecycle CDMO services. With the completion of this round of financing and the advancement of the Taizhou base construction, Haofeng is steadily progressing toward this goal.